"Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)" by Kami J. Maddocks

Selected Works of John M. Pagel, MD, PhD

Article

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2014)

Kami J. Maddocks, Ohio State University
John Pagel, Fred Hutchinson Cancer Research Center
John C. Byrd, Ohio State University
Scott Stromatt
Farrukh Awan, Ohio State University

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

December 6, 2014

Citation Information

Kami J. Maddocks, John Pagel, John C. Byrd, Scott Stromatt, et al.. "Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)" Blood Vol. 124 Iss. 21 (2014) p. 4671 - 4671
Available at: http://works.bepress.com/john-pagel/87/